<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383783</url>
  </required_header>
  <id_info>
    <org_study_id>17-I-112</org_study_id>
    <secondary_id>208705</secondary_id>
    <nct_id>NCT03383783</nct_id>
  </id_info>
  <brief_title>Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model</brief_title>
  <official_title>Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Domenick Zero</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the fluoride dose response of different dentifrice
      fluoride concentrations - 0, 250, 500 and 1100 ppm fluoride of our existing in situ model
      involving the use of human enamel specimens placed in the buccal flange area of the subjects
      partial denture with the modified model involving placement of bovine enamel specimens in a
      denture tooth location.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a double blind, single center, 4-way crossover design study involving 34 adult
      subjects, between the ages of 18 and 85 years. Two to three days before the start of each
      treatment period the subjects will have their teeth cleaned to remove all accessible plaque
      and calculus and will be provided with a non-fluoride dentifrice to use until their next
      visit. At the beginning of each testing period, two gauze-covered 4 × 4 mm partially
      demineralized human enamel specimens will be placed in the buccal flange area of the
      subject's mandibular partial denture. In addition, two gauze-covered 4 mm round partially
      demineralized bovine enamel specimens will be placed in the buccal surface of two posterior
      denture teeth of the same side of the partial denture. Once specimens are placed, subjects
      will wear their partial dentures twenty-four hours a day and use their assigned toothpaste
      twice daily, as instructed, until their next visit. Specimens will be removed after two weeks
      and the subjects will undergo a four to five day washout period followed by another cleaning
      and two to three day lead in period. This process will be repeated until all subjects have
      used all four test products. Changes in the mineral content of the enamel specimens will be
      assessed using the SMH and TMR. Enamel fluoride uptake (EFU) will be determined using the
      microdrill enamel biopsy technique. In addition the net acid resistance (NAR) and the
      comparative acid resistance (CAR) of the remineralized enamel specimens will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Actual">May 2, 2018</completion_date>
  <primary_completion_date type="Actual">May 2, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Surface Microhardness Recovery (%SMH)</measure>
    <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
    <description>The extent of remineralization will be calculated based on the method of [Gelhard et al., 1979].
SMH recovery = (D1-R)/(D1-B) ×100 B = indentation length (µm) of sound enamel specimen at baseline D1 = indentation length (µm) after in vitro demineralization R = indentation length (µm) after intra-oral exposure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Net Acid Resistance (NAR)</measure>
    <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
    <description>The %NAR will be calculated by the method of Corpron [Corpron et al., 1986]:
Net Acid Resistance = [(D1-D2) / (D1-B)] * 100 B= Indentation length (µm) of sound enamel at baseline D1= Indentation length (µm) after first in vitro demineralization D2= Indentation length (µm) after second in vitro demineralization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative Acid Resistance (CAR)</measure>
    <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
    <description>Using the data from the four centrally located enamel specimens, the equation used will compare explicitly the reduction in SMH brought by the first and second acid challenges:
Comparative Acid Resistance = [(D2-R) / (D1-B)] * 100 B= Indentation length (µm) of sound enamel at baseline R= Indentation length (µm) of enamel after in situ remineralization D1= Indentation length (µm) after first in vitro demineralization D2= Indentation length (µm) after second in vitro demineralization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enamel Fluoride Uptake (EFU)</measure>
    <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
    <description>The amount of fluoride-uptake by enamel will be calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as µg F/cm2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transverse Microradiography (TMR) - Integrated Mineral Loss - ∆Z</measure>
    <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
    <description>Lesions will be analyzed after in situ demineralization and the following three parameters calculated:
Integrated Mineral Loss - ∆Z= [(lesion depth x 87) - area under the curve*]
Lesion Depth - L (83% mineral i.e. 95% of the mineral content of sound enamel)
Maximum mineral density at the surface-zone - SZmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transverse Microradiography (TMR) - Lesion Depth - L</measure>
    <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
    <description>Lesions will be analyzed after in situ demineralization and the following three parameters calculated:
Integrated Mineral Loss - ∆Z= [(lesion depth x 87) - area under the curve*]
Lesion Depth - L (83% mineral i.e. 95% of the mineral content of sound enamel)
Maximum mineral density at the surface-zone - SZmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transverse Microradiography (TMR) - Maximum Mineral Density at the Surface-zone</measure>
    <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
    <description>Lesions will be analyzed after in situ demineralization and the following three parameters calculated:
Integrated Mineral Loss - ∆Z= [(lesion depth x 87) - area under the curve*]
Lesion Depth - L (83% mineral i.e. 95% of the mineral content of sound enamel)
Maximum mineral density at the surface-zone - SZmax (arbitrary unit from TMR software)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Caries</condition>
  <arm_group>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0 ppm F (placebo, negative control)</intervention_name>
    <description>Each subject will use this product during one of the four treatment periods in the crossover study design.</description>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_label>Treatment Period 4</arm_group_label>
    <other_name>Sensodyne sodium fluoride/silica toothpaste base formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>250 ppm F as NaF (dose-response control)</intervention_name>
    <description>Each subject will use this product during one of the four treatment periods in the crossover study design.</description>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_label>Treatment Period 4</arm_group_label>
    <other_name>Sensodyne sodium fluoride/silica toothpaste base formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 ppm F as NaF (dose-response control)</intervention_name>
    <description>Each subject will use this product during one of the four treatment periods in the crossover study design.</description>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_label>Treatment Period 4</arm_group_label>
    <other_name>Sensodyne sodium fluoride/silica toothpaste base formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1100 ppm F as NaF (positive control)</intervention_name>
    <description>Each subject will use this product during one of the four treatment periods in the crossover study design.</description>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_label>Treatment Period 4</arm_group_label>
    <other_name>Sensodyne sodium fluoride/silica toothpaste base formulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. provide voluntary, written informed consent;

          2. be between 18 and 85 years old;

          3. understand and be willing, able and likely to comply with all study procedures and
             restrictions;

          4. be wearing a removable mandibular partial denture with sufficient room in one
             posterior buccal flange area to accommodate two enamel specimens (required dimensions
             12 × 7 mm) and room on the same side to accommodate two 4 mm round specimens in the
             buccal surface of two posterior denture teeth;

          5. be willing and capable of wearing their removable partial denture 24 hours a day for
             four (4), two-week treatment periods;

          6. be willing to allow study personnel to drill specimen sites (as described #4) in their
             mandibular partial denture;

          7. be in good medical and dental health with no active caries or periodontal disease;
             NOTE; subjects presenting at screening with caries may continue in the study if their
             carious lesions are restored prior to beginning treatment 1.

          8. have a salivary flow rate in the range of normal values (unstimulated whole saliva
             flow rate ≥ 0.2 mL/min; gum base stimulated whole saliva flow rate ≥ 0.8 mL/min).

        Exclusion Criteria:

          1. currently be pregnant, intending to become pregnant during the study period or breast
             feeding;

          2. currently have any medical condition that could be expected to interfere with the
             subject's safety during the study period;

          3. currently be taking antibiotics or have taken antibiotics in the two weeks prior to
             the beginning treatment 1;

          4. have participated in another clinical study or receipt of an investigational drug
             within 30 days of beginning treatment 1; or

          5. be taking fluoride supplements, required to use a fluoride mouthrinse or have received
             a professional fluoride treatment in the two weeks preceding specimen placement;

          6. be taking or have ever taken bisphosphonate drugs (e.g., Fosamax, Actonel and Boniva)
             for the treatment of osteoporosis;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domenick T Zero, DDS, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anderson Hara, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Lippert, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University School of Dentistry, Oral Health Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <results_first_submitted>April 25, 2019</results_first_submitted>
  <results_first_submitted_qc>May 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2019</results_first_posted>
  <last_update_submitted>May 16, 2019</last_update_submitted>
  <last_update_submitted_qc>May 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Domenick Zero</investigator_full_name>
    <investigator_title>Director, Oral Health Research Institute</investigator_title>
  </responsible_party>
  <keyword>Caries</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Listerine</mesh_term>
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03383783/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1 participant signed the informed consent and attended up to visit 2, but were dropped from the study as they no longer met inclusion criteria, and this occurred before randomization to interventions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>This was a 4-way crossover design study. All participants were randomized to receive the following interventions:
Dentifrice fluoride concentrations - 0, 250, 500 and 1100 ppm fluoride of our existing in situ model involving the use of human enamel specimens placed in the buccal flange area of the subjects partial denture with the modified model involving placement of bovine enamel specimens in a denture tooth location.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>This was a 4-way crossover design study. All participants were randomized to receive the following interventions:
Dentifrice fluoride concentrations - 0, 250, 500 and 1100 ppm fluoride of our existing in situ model involving the use of human enamel specimens placed in the buccal flange area of the subjects partial denture with the modified model involving placement of bovine enamel specimens in a denture tooth location.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="37" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White/African-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Surface Microhardness Recovery (%SMH)</title>
        <description>The extent of remineralization will be calculated based on the method of [Gelhard et al., 1979].
SMH recovery = (D1-R)/(D1-B) ×100 B = indentation length (µm) of sound enamel specimen at baseline D1 = indentation length (µm) after in vitro demineralization R = indentation length (µm) after intra-oral exposure.</description>
        <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bovine Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O2">
            <title>Bovine Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O3">
            <title>Bovine Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O4">
            <title>Bovine Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O5">
            <title>Human Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O6">
            <title>Human Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O7">
            <title>Human Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O8">
            <title>Human Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Surface Microhardness Recovery (%SMH)</title>
          <description>The extent of remineralization will be calculated based on the method of [Gelhard et al., 1979].
SMH recovery = (D1-R)/(D1-B) ×100 B = indentation length (µm) of sound enamel specimen at baseline D1 = indentation length (µm) after in vitro demineralization R = indentation length (µm) after intra-oral exposure.</description>
          <units>Percent Surface Microhardness Recovery</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.96" lower_limit="8" upper_limit="20.29"/>
                    <measurement group_id="O2" value="30.59" lower_limit="22.26" upper_limit="38.71"/>
                    <measurement group_id="O3" value="40.74" lower_limit="31.68" upper_limit="50.34"/>
                    <measurement group_id="O4" value="48.28" lower_limit="37.15" upper_limit="57.86"/>
                    <measurement group_id="O5" value="7.42" lower_limit="2.55" upper_limit="12.45"/>
                    <measurement group_id="O6" value="16.27" lower_limit="10.33" upper_limit="22.51"/>
                    <measurement group_id="O7" value="21.59" lower_limit="13.67" upper_limit="29.64"/>
                    <measurement group_id="O8" value="26.75" lower_limit="18.19" upper_limit="35.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Acid Resistance (NAR)</title>
        <description>The %NAR will be calculated by the method of Corpron [Corpron et al., 1986]:
Net Acid Resistance = [(D1-D2) / (D1-B)] * 100 B= Indentation length (µm) of sound enamel at baseline D1= Indentation length (µm) after first in vitro demineralization D2= Indentation length (µm) after second in vitro demineralization</description>
        <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bovine Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O2">
            <title>Bovine Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O3">
            <title>Bovine Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O4">
            <title>Bovine Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O5">
            <title>Human Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O6">
            <title>Human Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O7">
            <title>Human Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O8">
            <title>Human Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
        </group_list>
        <measure>
          <title>Net Acid Resistance (NAR)</title>
          <description>The %NAR will be calculated by the method of Corpron [Corpron et al., 1986]:
Net Acid Resistance = [(D1-D2) / (D1-B)] * 100 B= Indentation length (µm) of sound enamel at baseline D1= Indentation length (µm) after first in vitro demineralization D2= Indentation length (µm) after second in vitro demineralization</description>
          <units>% Net Acid Resistance</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.68" lower_limit="-36.71" upper_limit="-11.7"/>
                    <measurement group_id="O2" value="11.43" lower_limit="1.92" upper_limit="20.42"/>
                    <measurement group_id="O3" value="18.66" lower_limit="8.17" upper_limit="27.63"/>
                    <measurement group_id="O4" value="31.79" lower_limit="17.57" upper_limit="42.9"/>
                    <measurement group_id="O5" value="-18.60" lower_limit="-28.62" upper_limit="-9.55"/>
                    <measurement group_id="O6" value="1.99" lower_limit="-6.31" upper_limit="9.43"/>
                    <measurement group_id="O7" value="8.31" lower_limit="-1.36" upper_limit="16.9"/>
                    <measurement group_id="O8" value="16.87" lower_limit="8.91" upper_limit="23.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative Acid Resistance (CAR)</title>
        <description>Using the data from the four centrally located enamel specimens, the equation used will compare explicitly the reduction in SMH brought by the first and second acid challenges:
Comparative Acid Resistance = [(D2-R) / (D1-B)] * 100 B= Indentation length (µm) of sound enamel at baseline R= Indentation length (µm) of enamel after in situ remineralization D1= Indentation length (µm) after first in vitro demineralization D2= Indentation length (µm) after second in vitro demineralization</description>
        <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bovine Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O2">
            <title>Bovine Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O3">
            <title>Bovine Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O4">
            <title>Bovine Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O5">
            <title>Human Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O6">
            <title>Human Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O7">
            <title>Human Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O8">
            <title>Human Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative Acid Resistance (CAR)</title>
          <description>Using the data from the four centrally located enamel specimens, the equation used will compare explicitly the reduction in SMH brought by the first and second acid challenges:
Comparative Acid Resistance = [(D2-R) / (D1-B)] * 100 B= Indentation length (µm) of sound enamel at baseline R= Indentation length (µm) of enamel after in situ remineralization D1= Indentation length (µm) after first in vitro demineralization D2= Indentation length (µm) after second in vitro demineralization</description>
          <units>% Comparative Acid Resistance</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.42" lower_limit="23.87" upper_limit="51.03"/>
                    <measurement group_id="O2" value="19.20" lower_limit="11.28" upper_limit="27.99"/>
                    <measurement group_id="O3" value="22.16" lower_limit="13" upper_limit="32.82"/>
                    <measurement group_id="O4" value="16.27" lower_limit="8.98" upper_limit="24.46"/>
                    <measurement group_id="O5" value="25.82" lower_limit="18.14" upper_limit="33.79"/>
                    <measurement group_id="O6" value="14.31" lower_limit="9.74" upper_limit="19.53"/>
                    <measurement group_id="O7" value="13.33" lower_limit="8.59" upper_limit="18.82"/>
                    <measurement group_id="O8" value="9.71" lower_limit="4.98" upper_limit="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enamel Fluoride Uptake (EFU)</title>
        <description>The amount of fluoride-uptake by enamel will be calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as µg F/cm2.</description>
        <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bovine Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O2">
            <title>Bovine Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O3">
            <title>Bovine Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O4">
            <title>Bovine Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O5">
            <title>Human Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O6">
            <title>Human Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O7">
            <title>Human Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O8">
            <title>Human Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
        </group_list>
        <measure>
          <title>Enamel Fluoride Uptake (EFU)</title>
          <description>The amount of fluoride-uptake by enamel will be calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as µg F/cm2.</description>
          <units>µg F/cm^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.73" upper_limit="1.16"/>
                    <measurement group_id="O2" value="2.25" lower_limit="1.94" upper_limit="2.56"/>
                    <measurement group_id="O3" value="2.69" lower_limit="2.35" upper_limit="2.97"/>
                    <measurement group_id="O4" value="2.98" lower_limit="2.62" upper_limit="3.27"/>
                    <measurement group_id="O5" value="0.96" lower_limit="0.77" upper_limit="1.15"/>
                    <measurement group_id="O6" value="2.14" lower_limit="1.9" upper_limit="2.38"/>
                    <measurement group_id="O7" value="2.50" lower_limit="2.32" upper_limit="2.71"/>
                    <measurement group_id="O8" value="2.73" lower_limit="2.48" upper_limit="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transverse Microradiography (TMR) - Integrated Mineral Loss - ∆Z</title>
        <description>Lesions will be analyzed after in situ demineralization and the following three parameters calculated:
Integrated Mineral Loss - ∆Z= [(lesion depth x 87) - area under the curve*]
Lesion Depth - L (83% mineral i.e. 95% of the mineral content of sound enamel)
Maximum mineral density at the surface-zone - SZmax</description>
        <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bovine Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O2">
            <title>Bovine Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O3">
            <title>Bovine Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O4">
            <title>Bovine Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O5">
            <title>Human Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O6">
            <title>Human Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O7">
            <title>Human Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O8">
            <title>Human Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
        </group_list>
        <measure>
          <title>Transverse Microradiography (TMR) - Integrated Mineral Loss - ∆Z</title>
          <description>Lesions will be analyzed after in situ demineralization and the following three parameters calculated:
Integrated Mineral Loss - ∆Z= [(lesion depth x 87) - area under the curve*]
Lesion Depth - L (83% mineral i.e. 95% of the mineral content of sound enamel)
Maximum mineral density at the surface-zone - SZmax</description>
          <units>Integrated Mineral Loss - ∆Z</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1240" lower_limit="948" upper_limit="1621"/>
                    <measurement group_id="O2" value="902" lower_limit="710" upper_limit="1136"/>
                    <measurement group_id="O3" value="664" lower_limit="546" upper_limit="803"/>
                    <measurement group_id="O4" value="684" lower_limit="552" upper_limit="841"/>
                    <measurement group_id="O5" value="1526" lower_limit="1250" upper_limit="1832"/>
                    <measurement group_id="O6" value="912" lower_limit="793" upper_limit="1033"/>
                    <measurement group_id="O7" value="901" lower_limit="800" upper_limit="1019"/>
                    <measurement group_id="O8" value="859" lower_limit="754" upper_limit="966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transverse Microradiography (TMR) - Lesion Depth - L</title>
        <description>Lesions will be analyzed after in situ demineralization and the following three parameters calculated:
Integrated Mineral Loss - ∆Z= [(lesion depth x 87) - area under the curve*]
Lesion Depth - L (83% mineral i.e. 95% of the mineral content of sound enamel)
Maximum mineral density at the surface-zone - SZmax</description>
        <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bovine Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O2">
            <title>Bovine Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O3">
            <title>Bovine Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O4">
            <title>Bovine Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O5">
            <title>Human Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O6">
            <title>Human Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O7">
            <title>Human Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O8">
            <title>Human Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
        </group_list>
        <measure>
          <title>Transverse Microradiography (TMR) - Lesion Depth - L</title>
          <description>Lesions will be analyzed after in situ demineralization and the following three parameters calculated:
Integrated Mineral Loss - ∆Z= [(lesion depth x 87) - area under the curve*]
Lesion Depth - L (83% mineral i.e. 95% of the mineral content of sound enamel)
Maximum mineral density at the surface-zone - SZmax</description>
          <units>Micrometers</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.01" lower_limit="40.62" upper_limit="65.49"/>
                    <measurement group_id="O2" value="41.74" lower_limit="32.58" upper_limit="53.38"/>
                    <measurement group_id="O3" value="34.85" lower_limit="27.39" upper_limit="43.65"/>
                    <measurement group_id="O4" value="27.31" lower_limit="22.62" upper_limit="32.18"/>
                    <measurement group_id="O5" value="60.73" lower_limit="50.56" upper_limit="71.99"/>
                    <measurement group_id="O6" value="42.12" lower_limit="34.28" upper_limit="49.8"/>
                    <measurement group_id="O7" value="37.38" lower_limit="31.17" upper_limit="45.06"/>
                    <measurement group_id="O8" value="36.02" lower_limit="31.03" upper_limit="41.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transverse Microradiography (TMR) - Maximum Mineral Density at the Surface-zone</title>
        <description>Lesions will be analyzed after in situ demineralization and the following three parameters calculated:
Integrated Mineral Loss - ∆Z= [(lesion depth x 87) - area under the curve*]
Lesion Depth - L (83% mineral i.e. 95% of the mineral content of sound enamel)
Maximum mineral density at the surface-zone - SZmax (arbitrary unit from TMR software)</description>
        <time_frame>Enamel specimens will be evaluated after 14 days of intra-oral exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bovine Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O2">
            <title>Bovine Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O3">
            <title>Bovine Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O4">
            <title>Bovine Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two bovine specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O5">
            <title>Human Specimens 0 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 0 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O6">
            <title>Human Specimens 250 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 250 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O7">
            <title>Human Specimens 500 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 500 parts per million fluoride dentifrice.</description>
          </group>
          <group group_id="O8">
            <title>Human Specimens 1100 Ppm F</title>
            <description>This arm group consisted of the two human specimens and 1100 parts per million fluoride dentifrice.</description>
          </group>
        </group_list>
        <measure>
          <title>Transverse Microradiography (TMR) - Maximum Mineral Density at the Surface-zone</title>
          <description>Lesions will be analyzed after in situ demineralization and the following three parameters calculated:
Integrated Mineral Loss - ∆Z= [(lesion depth x 87) - area under the curve*]
Lesion Depth - L (83% mineral i.e. 95% of the mineral content of sound enamel)
Maximum mineral density at the surface-zone - SZmax (arbitrary unit from TMR software)</description>
          <units>SZmax</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.17" lower_limit="59.59" upper_limit="64.44"/>
                    <measurement group_id="O2" value="62.54" lower_limit="60.14" upper_limit="65.14"/>
                    <measurement group_id="O3" value="67.13" lower_limit="63.53" upper_limit="70.61"/>
                    <measurement group_id="O4" value="65.93" lower_limit="60.31" upper_limit="70.88"/>
                    <measurement group_id="O5" value="61.22" lower_limit="58.82" upper_limit="63.62"/>
                    <measurement group_id="O6" value="62.99" lower_limit="60.59" upper_limit="65.42"/>
                    <measurement group_id="O7" value="61.38" lower_limit="59.32" upper_limit="63.24"/>
                    <measurement group_id="O8" value="63.66" lower_limit="61.14" upper_limit="66.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each participant was monitored for a 3 month period.</time_frame>
      <desc>The collection/monitoring of adverse events started at visit 2 (prior to randomization), at which time there were 28 eligible subjects. Human and bovine specimens were both placed on the same side of the lower partial dentures in 27 subjects at visit 3 (randomization), and from that point forward adverse events were monitored based on the assigned treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>0 Ppm F</title>
          <description>0 parts per million fluoride</description>
        </group>
        <group group_id="E2">
          <title>250 Ppm F</title>
          <description>250 parts per million fluoride</description>
        </group>
        <group group_id="E3">
          <title>500 Ppm F</title>
          <description>500 parts per million fluoride</description>
        </group>
        <group group_id="E4">
          <title>1100 Ppm F</title>
          <description>1100 parts per million fluoride</description>
        </group>
        <group group_id="E5">
          <title>Between Treatment Periods</title>
          <description>Adverse Events that occurred between treatment periods.</description>
        </group>
        <group group_id="E6">
          <title>Prior to Randomization</title>
          <description>Adverse Events that occurred prior to a subject being randomized into the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mouth Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gum Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Loose Crown</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Lost Filling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mucosal White Patch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Oral Burning Sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Tooth Extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common Cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Enlarged Lymphnode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Infected Cysts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Swollen Eye Lid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Head Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hip Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Leg Cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Muscle Stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasal Epitaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sinus Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Domenick T Zero, DDS, MS</name_or_title>
      <organization>Oral Health Research Institute</organization>
      <phone>317-274-8822</phone>
      <email>dzero@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

